ACT-389949
CAS No. 1258417-54-7
ACT-389949 ( —— )
Catalog No. M23429 CAS No. 1258417-54-7
ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 311 | In Stock |
|
10MG | 441 | In Stock |
|
25MG | 707 | In Stock |
|
50MG | 981 | In Stock |
|
100MG | 1332 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameACT-389949
-
NoteResearch use only, not for human use.
-
Brief DescriptionACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes.
-
DescriptionACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorFPR2/ALX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1258417-54-7
-
Formula Weight428.4
-
Molecular FormulaC20H18F2N6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mg/mL (23.34 mM; ultrasonic and adjust pH to 1 with HCl)
-
SMILESO=C(NC1=NN(N=C1)CC2=NC(C(F)(C)F)=CO2)C3=C(OC(C)=N3)C4=CC=CC(C)=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Stalder AK,et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83(3):476-486.
molnova catalog
related products
-
Pirmenol
Pirmenol is?a new antiarrhythmic drug.
-
Myricoside
Myricoside is a natural product isolated from the aerial parts of Phlomis oppositiflora.
-
Hederasaponin B
Hederasaponin B has antiviral activity, via inhibiting the viral VP2 protein expression and blocking viral capsid protein synthesis.